STOCK TITAN
  1. Home
  2. News
  3. RDY

Dr. Reddy`s Laboratories Ltd. - RDY STOCK NEWS

Welcome to our dedicated news page for Dr. Reddy`s Laboratories Ltd. (Ticker: RDY), a resource for investors and traders seeking the latest updates and insights on Dr. Reddy`s Laboratories Ltd..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Dr. Reddy`s Laboratories Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Dr. Reddy`s Laboratories Ltd.'s position in the market.

News
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
Rhea-AI Summary
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) biosimilar in the UK for treating various cancers, following successful launches in India and other countries. The product is a potential treatment option for metastatic colorectal cancer, advanced lung, brain, renal, cervical, ovarian, and breast cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
none
-
News
Dr. Reddy’s Q3 & 9M FY24 Financial Results
Rhea-AI Summary
Dr. Reddy’s Laboratories Ltd. announced consolidated financial results for Q3FY24 and 9MFY24, with a 7% YoY revenue increase. The company reported a 58.5% gross margin for Q3FY24 and a 30.9% EBITDA margin for 9MFY24. Dr. Reddy’s Laboratories also highlighted key business developments and ESG achievements, positioning the company as a leader in the pharmaceutical industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.69%
Tags
earnings
-
News
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands
Rhea-AI Summary
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) has acquired MenoLabs® business, a leading women’s health and dietary supplement branded portfolio from Amyris, Inc. The acquisition includes seven branded products designed to provide health support and address symptoms of perimenopause and menopause, along with the MenoLife® health tracker app. This deal will accelerate Dr. Reddy's growth in the women’s nutritional and wellness markets, complementing their U.S. self-care and wellness business portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
acquisition
News
Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
Rhea-AI Summary
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) has achieved significant milestones in sustainability and Environment Social and Governance (ESG) initiatives. The company has secured 'Gold Medal' status from the global sustainability ratings agency, EcoVadis, and is featured in the Dow Jones Sustainability World Index for 2023, marking its debut in the index. Dr. Reddy's also retains its place in the Dow Jones Sustainability Emerging Markets Index for the 8th consecutive year. It has become the first Indian pharma company to pledge towards an integrated plantation initiative covering 2,900 hectares by 2028 as part of the World Economic Forum's 1t.org.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
none
-
News
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Rhea-AI Summary
Dr. Reddy's Laboratories SA (NYSE: RDY) and Coya Therapeutics, Inc. (NASDAQ: COYA) have entered into a development and license agreement for the commercialization of COYA 302, an investigational combination therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS). The agreement grants Dr. Reddy's the exclusive rights to commercialize COYA 302 in the United States, Canada, the European Union, and the United Kingdom. The agreement includes an upfront payment of USD 7.5 million to Coya, with additional milestone payments of up to USD 40 million and sales-based milestone payments of up to USD 677.25 million. Dr. Reddy's will also pay royalties based on a percentage of net sales of COYA 302 ranging from low to middle teens. The development of COYA 302 was a result of a research collaboration between Coya and Houston Methodist in the laboratory of Dr. Stanley Appel.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
none
-
News
Dr. Reddy’s Q2 FY24 Financial Results
Rhea-AI Summary
Dr. Reddy’s Laboratories Ltd. announces its consolidated financial results for Q3 2023. Revenues increased by 9% YoY and 2% QoQ. Gross margin is 58.7%. SG&A expenses increased by 13% YoY and 6% QoQ. R&D expenses are 7.9% of revenues. EBITDA is 31.7% of revenues. Profit before Tax increased by 19% YoY and 4% QoQ. Profit after Tax increased by 33% YoY and 6% QoQ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
earnings
News
Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
Rhea-AI Summary
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) announced the launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. market, a generic version of KOMBIGLYZE® XR tablets. The tablets are approved by the USFDA and come in strengths of 2.5 mg/1000 mg and 5 mg/500 mg and 5 mg/1000 mg. The company also provided a link to the full prescribing information, including a boxed warning for LACTIC ACIDOSIS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
none
-
News
Dr. Reddy’s Q1 FY24 Financial Results
Rhea-AI Summary
Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for Q2 2023. Revenues increased by 29% YoY and 7% QoQ. Gross margin improved to 58.7%. Profit before tax increased by 26% YoY and 39% QoQ. Profit after tax increased by 18% YoY and 46% QoQ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
earnings
-
News
Dr. Reddy’s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
Rhea-AI Summary
Dr. Reddy’s Laboratories announced that its Biologics License Application for its proposed biosimilar rituximab candidate DRL_RI has been accepted for review by the USFDA, EMA, and MHRA. The company expects to bring more biosimilar products to meet patient needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
none
News
Dr. Reddy’s Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab
Rhea-AI Summary
Dr. Reddy's tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase I study. The study demonstrated pharmacokinetic equivalence, safety, and immunogenicity compared to reference products. Dr. Reddy's is now initiating a global Phase III study to compare efficacy, safety, tolerability, and immunogenicity with the reference product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
clinical trial
Stock RDY logo
Dr. Reddy`s Laboratories Ltd.

NYSE:RDY

RDY Rankings

#700 Ranked by Market Cap
#918 Ranked by Stock Gains
#1954 Ranked by Dividends

RDY Stock Data

12.16B
119.82M
15.03%
0.38%
Medicinal and Botanical Manufacturing
Manufacturing
Link
India
Hyderabad

About RDY

They are an Indian multinational pharmaceutical company located in Hyderabad, Telangana, India. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited.